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had high regional prevalence of AF in 2011. Geographic variation in high risk 
areas can help identify important geographically connected prognostic factors, 
aid in targeted intervention strategies, and generate hypotheses regarding 
underlying causes of AF in the United States and associated territories.  
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OBJECTIVES: To estimate the disease burden of atrial fibrillation and to describe 
its impact on Colombian population health METHODS: We calculated Disability 
Adjusted Life Year (DALYs) for atrial fibrillation, by adding years of life lost due 
to premature mortality (YLL) plus years lived with disability (YLD). For 
calculating YLL it were consulted both death registration and abridged-life tables 
at national statistic agency DANE for 2000-2009. For calculating YLD it were 
consulted individual records of service providers for 2009-2010. It were also 
consulted the map of weighted disability from the Global Burden of Disease 
study. For data processing we used a template developed in Microsoft Excel® 
according to the method described by WHO in October 2001 and taking into 
account the parameters and formulas that have been described by Murray and 
Lopez (1996) and Mathers et al (2001). RESULTS: In 2000, 2004 and 2009 it was lost 
due to atrial fibrillation 12,138; 13,188 and 15,327 DALYs in the Colombian 
population with a ratio of 0.30, 0.31 and 0.34 DALY per thousand people 
respectively. The relative weight of DALYs was given by the disability component 
(91.46%). Men accounted for an average of 58% of estimated DALYs; and the most 
affected age was that of 70-79 years old CONCLUSIONS: The estimated DALYs 
show that atrial fibrillation is a disease highly disabling in the Colombian 
population during the study period, given the predominance of the component 
of years lived with disability (YLD).  
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OBJECTIVES: Most of the studies of time distribution of stroke onset in the 
Chinese population have a limited number of cases, and national-level data 
analysis is rare. In this study, circadian rhythm of stroke onset in the Chinese 
patients was observed on the basis of the China National Stroke Registry (CNSR) 
data. METHODS: Continuous prospective registration of new-onset acute 
cerebrovascular events within 14 days was conducted based on nationwide 
multi-center, continuity, prospective stroke registry data, and 1-year follow-up 
was performed to analyze the differences in time pattern and prognosis of the 
onset of strokes of different etiological subtypes and clinical sub-types. 
RESULTS: A total of 9588 people entered the statistical description after cases 
with absence of time of onset and wake-up stroke were excluded from all of the 
stroke cases (including IS, ICH, SAH, TIA). The period from 7:00 to 12:00 appeared 
to be a significant peak for stroke onset. According to different stroke sub-types, 
onset peak in the morning was more prominent in 5796 cases of IS and 399 cases 
of TIA; 2,666 cases of ICH and 399 cases of SAH presented two onset peaks from 
7:00 to 12:00 and from 17:00 to 19:00. The cases showed the same trend 
irrespective of initial onset or recurrence and with or without hypertension. 
Through logistic regression model analysis, gender, age, history of Arial 
Fibrillation, smoking history and other factors were related to the time of stroke 
onset to a certain extent. CONCLUSIONS: The time of stroke onset in Chinese 
patients is generally in the morning. The trend of IS onset is particularly evident. 
Therefore, paying more attention to morning care and blood pressure control 
during morning will be important.  
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OBJECTIVES: Heart Failure (HF) is a leading cause of morbidity and mortality in 
the US, and hospitalization for HF appears to be steadily increasing. We sought 
to identify HF patients and understand the patterns of care for HF in a real-world 
setting through analysis of a retrospective observational database. METHODS: 
The study population consisted of patients in the Medicare 5% database with a 
primary inpatient diagnosis of HF (ICD-9-CM 428.0, 428.9, 428.20-23, 428.30–33, 
428.40–43) during CY2005–2008. Patients were followed for up to 33 months (6 
months baseline, 3 month index, 24 months follow-up. To exclude prevalent 
cases, patients were required to have no diagnoses of HF in the baseline period. 
The quarter of the initial HF inpatient diagnosis was designated the “index 
quarter”. Each patient was followed for up to two years (8 quarters) after the 
index quarter, or until death or end of enrolment. Frequency of service use based 
on care setting; diagnosis was determined for the “index quarter” and follow-up 
period. RESULTS: A total of 43,819 patients with new primary HF inpatient 
claims were identified in the four year study period. Within the 27 month follow-
up (includes “index”), the identified HF patients had 140,802 inpatient 
hospitalizations (3.2 per patient), of which 66,334 (1.5 per patient) had a primary 
HF diagnosis (includes index HF hospitalization). 23% of identified HF patients 
had one or more HF hospitalizations within two years after the “index”. 
Annualized mortality was 26.4%/year over the first five quarters (includes 
“index”) and 14%/year over quarters 5 through 8. Total mortality was 42.4% 
(18,562/43,819). CONCLUSIONS: Extrapolation of these results suggest that new 
inpatient HF admissions may account for 145,000 HF inpatient hospitalizations. 
HF Mortality after the “index” admission was >40%. Our results underline HF as a 
major clinical and economic burden in the United States.  
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OBJECTIVES: To identify the long term effects of common symptoms of 
pregnancy and whether these increase the risk of cardiovascular disease or 
symptoms associated with it in women at 21 years after pregnancy. METHODS: 
Data used were from the Mater University Study of Pregnancy (MUSP), a 
community- based prospective birth cohort study begun in Brisbane, Australia, 
in 1983. Chi square test and logistic regression analyses were conducted. 
RESULTS: Data were available for 3692 women. In cross tabulations, morning 
sickness, heartburn and backache show positive association (p<0.05) with 
different cardiovascular outcomes. However, in the multivariate models, only 
those experiencing heartburn (adjusted OR 1.3, 95% CI 1.0-1.7) during pregnancy 
were at greater risk of having hypertension 21 years post partum. Women 
experiencing morning sickness (adjusted OR 1.2, 95% CI 0.8-2.0) and backache 
(adjusted OR 1.1, 95% CI 0.6-1.7) were not considered to be at risk for future heart 
disease. CONCLUSIONS: As a whole, our study suggests that most common 
symptoms of pregnancy are not associated with an increased risk of 
cardiovascular disease or with hypertension in the long term.  
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OBJECTIVES: Dronedarone and warfarin are commonly used concurrently in the 
treatment and prevention of stroke caused by atrial fibrillation. Previous data 
from clinical trials suggest a drug-drug interaction between warfarin and 
dronedarone should exist. However, the dosing strategy of warfarin related to 
dronedarone remained unclear in real-world settings. This observational study 
aimed to assess the effect of starting dronedarone in patients with stable INRs in 
daily practice. METHODS: A case-control design was employed. Patients with 
prior stable INRs who started dronedarone between July 2009 and May 2011 were 
identified. After dronedarone was added, subjects with unstable INRs were cases 
and those remaining stable INRs were controls. Data were retrospectively 
collected via charts review. Primary outcomes were pharmacist-judged unstable 
INR status and required warfarin dose adjustments to reach stable INRs again. 
Secondary outcomes were post-INRs and safety measures. Pre-post changes 
were assessed using paired t-tests. Exploratory logistic and linear regression 
models were used to identify predictors for primary outcomes. RESULTS: Of 131 
subjects, 44 (33.6%) were cases. A difference in baseline characteristics between 
groups was a target INR range not 2.0-3.0 (p=0.030), which remains a predictor of 
unstable INRs after adjustments for confounders (OR=7.95, 95% CI 1.58-40.09, 
p=0.012). Forty subjects (30.5%) had increased INRs >0.5, and two (1.5%) had ER 
visits. No dose adjustment was made in controls. Compared to pre-doses, post-
doses were significantly reduced in cases (-5.14 mg or -14.3%, p<0.001). Absolute 
dose changes were associated with pre-dose (p<0.001), INR target not 2.0-3.0 
(p=0.028) and degree of post-INRs deviated from the target (p<0.001). When the 
outcomes were dose changes in percentage, only the latter remained a predictor 
(p<0.001). CONCLUSIONS: After dronedarone was added, warfarin doses were 
downward adjusted in about one-third of patients. The potential drug-drug 
interaction between dronedarone and warfarin should be considered in clinical 
practice.  
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OBJECTIVES: Increasing prevalence of heart failure (HF), increasing enrollment in 
state programs, and the economic burden of hospitalization among Medicaid 
patients necessitate an assessment of the budget impact of key risk factors for 
HF patients in a contemporary Medicaid population. METHODS: Claims from 
Maryland Medicaid, for 14,149 non-dual enrolled, 18-64 year olds with an HF 
diagnosis between July 1, 2005- December 31, 2009, follow-up >=six months. 
Weighted Cox Regression estimated average risk of any hospitalization 
attributable to various comorbidities and first-line therapy use, controlling for 
confounders. Noting the prevalence of comorbidity and therapy use, and mean 
cost of primary HF hospitalization for non-dual enrolled Maryland Medicaid 
patients in 2010 ($16,963 in 2011 dollars), numbers-needed-to-treat (NNT) were 
used to conservatively estimate the expected annual impact to the Maryland 
Medicaid budget attributable to 20% increases in prescribing rates (comorbidity 
prevalence) and associated reduction (increase) in hospitalization rates. 
RESULTS: Most patients were >45 years (71%), female (56%), and black (60%).  
Use prevalence was: beta-blockers (26%), ACE-inhibitors/ARB (29%), aldosterone 
antagonists (AA, 5%), and others including nitrates+hydralazine (37%). 
Comorbidity prevalence: hypertension (73%), psychological disorder (55%), 
chronic ischemic heart disease (CIHD, 43%), diabetes (41%), hyperlipidemia (37%), 
